Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahnaz Shekari

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 22, 2021
Visual assessment of [<sup>18</sup>F]flutemetamol PET images can detect early amyloid pathology and grade its extentLyduine E Collij, Gemma Salvadó, Mahnaz Shekari, et al.
EMBO Molecular Medicine|November 2, 2021
P-tau235: a novel biomarker for staging preclinical Alzheimer's diseaseJuan Lantero-Rodriguez, Anniina Snellman, Andrea L Benedet, et al.
Ebiomedicine|May 25, 2025
A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's diseaseArmand González-Escalante, Marta Milà-Alomà, Wagner S Brum, et al.
The Lancet. Healthy Longevity|March 31, 2024
The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort studyIrene Cumplido-Mayoral, Anna Brugulat-Serrat, Gonzalo Sánchez-Benavides, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 20, 2024
CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's diseaseNoëlle Warmenhoven, Gonzalo Sánchez-Benavides, Armand González-Escalante, et al.
Neurology|June 11, 2024
Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease HeterogeneitySophie E Mastenbroek, Arianna Sala, David Vállez García, et al.
Neurobiology of Aging|June 26, 2026
Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individualsDavid López-Martos, Marc Suárez-Calvet, Gemma Salvadó, et al.
Alzheimer'S Research & Therapy|February 18, 2021
Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's diseaseOriol Grau-Rivera, Irene Navalpotro-Gomez, Gonzalo Sánchez-Benavides, et al.
Alzheimer'S Research & Therapy|December 24, 2024
Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's diseaseGeorgette Argiris, Muge Akinci, Cleofé Peña-Gómez, et al.
Alzheimer'S Research & Therapy|July 28, 2021
Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profileMarta Milà-Alomà, Mahnaz Shekari, Gemma Salvadó, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
European Journal of Nuclear Medicine and Molecular Imaging|February 22, 2021
Visual assessment of [<sup>18</sup>F]flutemetamol PET images can detect early amyloid pathology and grade its extentLyduine E Collij, Gemma Salvadó, Mahnaz Shekari, et al.
EMBO Molecular Medicine|November 2, 2021
P-tau235: a novel biomarker for staging preclinical Alzheimer's diseaseJuan Lantero-Rodriguez, Anniina Snellman, Andrea L Benedet, et al.
Ebiomedicine|May 25, 2025
A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's diseaseArmand González-Escalante, Marta Milà-Alomà, Wagner S Brum, et al.
The Lancet. Healthy Longevity|March 31, 2024
The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort studyIrene Cumplido-Mayoral, Anna Brugulat-Serrat, Gonzalo Sánchez-Benavides, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 20, 2024
CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's diseaseNoëlle Warmenhoven, Gonzalo Sánchez-Benavides, Armand González-Escalante, et al.
Neurology|June 11, 2024
Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease HeterogeneitySophie E Mastenbroek, Arianna Sala, David Vállez García, et al.
Neurobiology of Aging|June 26, 2026
Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individualsDavid López-Martos, Marc Suárez-Calvet, Gemma Salvadó, et al.
Alzheimer'S Research & Therapy|February 18, 2021
Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's diseaseOriol Grau-Rivera, Irene Navalpotro-Gomez, Gonzalo Sánchez-Benavides, et al.
Alzheimer'S Research & Therapy|December 24, 2024
Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's diseaseGeorgette Argiris, Muge Akinci, Cleofé Peña-Gómez, et al.
Alzheimer'S Research & Therapy|July 28, 2021
Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profileMarta Milà-Alomà, Mahnaz Shekari, Gemma Salvadó, et al.
Pageof 6